Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio Key International (BKYI) EBITDA Margin (2016 - 2025)

Bio Key International's EBITDA Margin history spans 16 years, with the latest figure at 67.03% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 3679.0% year-over-year to 67.03%; the TTM value through Sep 2025 reached 67.87%, up 204.0%, while the annual FY2024 figure was 61.68%, 4479.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 67.03% at Bio Key International, down from 65.33% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 26.25% in Q1 2024 and bottomed at 386.84% in Q4 2022.
  • The 5-year median for EBITDA Margin is 96.42% (2024), against an average of 108.75%.
  • The largest annual shift saw EBITDA Margin surged 34732bps in 2021 before it tumbled -17299bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 213.85% in 2021, then plummeted by -81bps to 386.84% in 2022, then surged by 68bps to 122.45% in 2023, then rose by 21bps to 96.42% in 2024, then surged by 30bps to 67.03% in 2025.
  • Per Business Quant, the three most recent readings for BKYI's EBITDA Margin are 67.03% (Q3 2025), 65.33% (Q2 2025), and 45.41% (Q1 2025).